EBioMedicine (Aug 2022)

Timing evolution of lobular breast cancer through phylogenetic analysis

  • Danai Fimereli,
  • David Venet,
  • Mattia Rediti,
  • Bram Boeckx,
  • Marion Maetens,
  • Samira Majjaj,
  • Ghizlane Rouas,
  • Caterina Marchio,
  • Francois Bertucci,
  • Odette Mariani,
  • Maria Capra,
  • Giuseppina Bonizzi,
  • Federica Contaldo,
  • Christine Galant,
  • Gert Van den Eynden,
  • Roberto Salgado,
  • Elia Biganzoli,
  • Anne Vincent-Salomon,
  • Giancarlo Pruneri,
  • Denis Larsimont,
  • Diether Lambrechts,
  • Christine Desmedt,
  • David N. Brown,
  • Françoise Rothé,
  • Christos Sotiriou

Journal volume & issue
Vol. 82
p. 104169

Abstract

Read online

Summary: Background: Late distant recurrence is a challenge for the treatment of invasive lobular carcinoma (ILC) of the breast. Despite in-depth characterisation of primary ILC, the molecular landscape of metastatic ILC is still only partially understood. Methods: We retrospectively identified 38 ILC patients from the tissue banks of six European institutions. DNA extracted from patient matched primary and metastatic FFPE tissue blocks was whole genome sequenced to compute somatic copy number aberrations. This, in turn, was used to infer the evolutionary history of these patients. Findings: The data show different metastatic seeding patterns, with both an early and late divergence of the metastatic lineage observed in ILC. Additionally, cascading dissemination from a metastatic precursor was a dominant rule. Alterations in key cancer driver genes, such as TP53 or CCND1, were acquired early while additional aberrations were present only in the metastatic branch. In about 30% of the patients, the metastatic lineage harboured less aberrations than the primary tumour suggesting a period of tumour dormancy or prolonged adaptation at the distant site. This phenomenon was mostly observed in tumours from de novo metastatic patients. Interpretation: Our results provide insights into ILC evolution and offer potential paths for optimised ILC care. Funding: This work has received financial support from Les Amis de l'Institut Bordet, MEDIC, the Breast Cancer Research Foundation (BCRF) and the Belgian Fonds National de la Recherche Scientifique (F.R.S-FNRS).

Keywords